European Human Biomonitoring Initiative (HBM4EU)

Transcription

1 European Human Biomonitoring Initiative (HBM4EU) HBM4EU is a joint effort of 28 countries, the European Environment Agency (EEA) and the European Commission, co funded by Horizon 2020

2 Keeping an eye on chemicals European Commission (2001): Global production of chemicals increased from 1 Mt in 1930 to 400 Mt in 2001 June 2015: Chemical Abstracts Service (CAS) assigned 100 Mt CAS Registry Number Chemical industry is Europe s 3rd largest manufacturing industry Eurostat: about 30 Mt of carcinogenic, mutagenic and reprotoxic chemicals produced in 2009

3 Relevant Regulations in EU

4 Why do we need HBM4EU? To better understand the consequences of human exposure to chemicals (a key aspect of environmental health) To bridge the gap between science and policy making To share evidence of use from national programmes To share existing experience in EU To generate better evidence for better regulation To give better access by a new data infrastructure (Information Platform for Chemical Monitoring IPChem) To include aggregate exposure in the health risk assessment

5 HBM4EU patners 22 EU Member States 5 Associated States (Insland, Norway, Luxembourg, Hungary, Israel) EEA Switzerland

6 HBM4EU: Science to support policy Aims Work programme designed especially to answer open policy relevant question Give policy makers a fast and easy access to results and data Bridge the gap between science and policy

7 Objectives of the project Harmonize procedures and tools for HBM at EU level Provide and generate internal exposure data (where missing) Link data to external exposure and relevant exposure pathways Develop novel methods to identify human internal exposure to environmental and occupational chemicals Provide policy makers and general public science based knowledge on the health risks Improve chemical risk assessment in the EU (effective use of HBM data) Establish an EU wide base of human exposure data (IPCheM)

8 Structure of HBM4EUC The activities developed to deliver these objectives are organized into several work packages clustered under three pillars

9 The role of Italy EPIUD IUSS DEP UniMoRe DPH National Hub Contact Point Chemical Group Leader (CrVI) EPIUD: University of Udine IUSS: Institute for Advanced Study of Pavia UniMore: University of Modena and Reggio Emilia DEP: Department of Epidemiology Asl Roma DPH: University of Naples Federico II ISS Linked third Parties

10 The role of Italy ISS and its linked third parts are involved in: WP7, identification of existing national HBM studies and data gaps WP8, comparability and alignment of national HBM surveys at EU level WP10, statistical analysis of national HBM data to generate European reference values and integration of national data into IPChem portal WP11, provide the link between HBM levels and health data WP12, develop an exposure modeling computational framework with HBM WP13, support the relationship between exposure to a substance and health effects WP14, selection of biomarkers of effects according to their utility

11 The role of Italy In the first work plan (2017), Italy contributed to the HBM4EU initiative with the following substances/cohorts/matrices: Chemical substances Cohorts Matrices Measurement techniques Cadmium Adult population Blood and serum ICP-MS Chromium (VI) Children population Erytrocites ICP-MS, GC-MS/MS Per-/polyfluorinated compounds Polycyclic aromatic hydrocarbons Mother/child Workers Nulliparous women Urine Hair Saliva LC-MS/MS Chemical mixtures

12 What has been done Prioritization exercise: Initial horizon scanning to identify 1rst year substances with input from 22 countries To identify in each country a priority list of 10 substances of most interest: that are of concern to human health where there is evidence of human/ environmental exposure at EU Level of high relevance for policy use with open policy questions

13 What has been done Specific questions for the prioritization exercise: Which is the health relevance? Exposure evidence / potential health impact evidence/ public concern What is the level of knowledge? Experiences in country / methodology available /data to share available Which are the specific research questions to be answered? Exposure sources/ health outcomes/ causal link between exposure and human health Which is the expected use for policies? Which actions are expected from HBM4EU project?

14 Outputs (Deliverable 7.1) Absence of EU studies focused on the anilin family Very few studies on CrVI and emerging chemicals

15 List of priority substances resulting from consultation (1 st year)

16 Prioritization rounds under HBM4EU 2nd round of prioritisation in 2017 and 2018 will generate the 2nd list of HBM4EU priority substances, for inclusion in the 2019 and 2020 work plans 3rd round of prioritisation in 2019 and 2020 will generate the 3rd list of HBM4EU priority substances for inclusion in the 2021 work plan the aim of develop a harmonized and sustainable European HBM initiative post 2021

17 Prioritization strategy and criteria

18 Outputs HBM4EU produces a range of results available via website, direct communication and other dissemination channels (newsletter)

19 Future actions The scoping documents contain review of the available evidence list policy related questions identify knowledge gaps propose research activities

20 Future actions (CrVI) Provide HBM data of occupational exposure Provide HBM data of the general population at low level environmental exposures Provide information on reliability of blood, urine and RBCs as a biomonitoring tools Validate the above mentioned biomarkers of exposure Develop and harmonize methodological approaches Identify HBM reference values and toxicologically derived HBM guidance values

21 Grazie per l attenzione alessandro.alimonti@iss.it